Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cells

Belgique Nouvelles Nouvelles

Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cells
Belgique Dernières Nouvelles,Belgique Actualités
  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 13 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 51%

The lining of children's noses may provide protection from SARS-CoV-2 infection plos PLOSBiology

Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia, Department of Infectious Diseases, Perth Children’s Hospital, Nedlands, Perth, Western Australia, Australia, Wesfarmers Centre for

Vaccines and Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

medical_xpress /  🏆 101. in UK

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Decoy ACE2 receptors broadly neutralize SARS-CoV-2 variantsDecoy ACE2 receptors broadly neutralize SARS-CoV-2 variantsDecoy ACE2 receptors broadly neutralize SARS-CoV-2 variants ACE2 Coronavirus Disease COVID SARSCoV2 CellPressNews osaka_univ_e KyotoU_News
Lire la suite »

SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model - Nature CommunicationsSARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model - Nature CommunicationsMolnupiravir was the first orally available SARS-CoV-2 antiviral approved for outpatient use against SARS-CoV-2, but its efficacy against variants of concern, especially delta, was questioned. Here the authors evaluate molnupiravir against variant of concern in numerous models, including human airway epithelium organoids, ferrets and Roborovski dwarf hamsters.
Lire la suite »

The recent progress in investigating the inhibitory impact of nanosponges and antiviral delivery against SARS-CoV-2The recent progress in investigating the inhibitory impact of nanosponges and antiviral delivery against SARS-CoV-2The recent progress in investigating the inhibitory impact of nanosponges and antiviral delivery against SARS-CoV-2 StanfordMed nanosponge SARSCoV2 COVID19 coronavirus covid antiviral
Lire la suite »

Study indicates that cross-reactive immunity against SARS-CoV-2 N protein was present in Africa prior to the pandemicStudy indicates that cross-reactive immunity against SARS-CoV-2 N protein was present in Africa prior to the pandemicResearchers assessed the pre-existing cross-protective immune responses against SARS-CoV-2 nucleocapsid protein and spike protein before the COVID-19 pandemic in individuals residing in North and South America, Europe and Africa in vitro and in vivo.
Lire la suite »

Community spread of COVID-19 in New York City revealed by contact tracingCommunity spread of COVID-19 in New York City revealed by contact tracingCommunity spread of COVID-19 in New York City revealed by contact tracing researchsquare Columbia WeillCornell COVID19 coronavirus covid NewYork contacttracing
Lire la suite »

The recent progress in investigating the inhibitory impact of nanosponges and antiviral delivery against SARS-CoV-2The recent progress in investigating the inhibitory impact of nanosponges and antiviral delivery against SARS-CoV-2The recent progress in investigating the inhibitory impact of nanosponges and antiviral delivery against SARS-CoV-2 StanfordMed nanosponge SARSCoV2 COVID19 coronavirus covid antiviral
Lire la suite »



Render Time: 2025-04-19 00:27:28